AFFILIATIONS
1 Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, Bologna, Italy, Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
2 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy, Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
4 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
5 Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States
6 Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States
8 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy, Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
9 Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
10 Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
11 Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada
12 Pediatric Hematology Unit, Hospital de Dona Estefânia, ULS São José, Lisbon, Portugal
13 Experimental Haematology Lab, IIS- Fundación Jimenez Díaz, UAM, Madrid, Spain
14 Experimental Haematology Lab, IIS- Fundación Jimenez Díaz, UAM, Madrid, Spain
15 Pediatric Hematology Unit, Hospital de Dona Estefânia, ULS São José, Lisbon, Portugal
16 Medical University of Vienna, Department of Pediatrics and Adolescent Medicine, Vienna, Austria, St. Anna Children's Hospital, Vienna, Austria
17 Bone Marrow Transplantation Unit, Department of Pediatric Hematology and Oncology, National Institute of Children's Diseases, Comenius University, Bratislava, Slovakia
18 Bone Marrow Transplantation Unit, Department of Pediatric Hematology and Oncology, National Institute of Children's Diseases, Comenius University, Bratislava, Slovakia
19 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
20 Medical Genetics Unit, Policlinico Tor Vergata, University of Rome Tor Vergata, Rome, Italy
21 Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
22 Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
23 Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi University of Florence, Florence, Italy
24 Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I-Sapienza University, Rome, Italy
25 Myeloid Malignancies Research Group, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain
26 Myeloid Malignancies Research Group, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain
27 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy, Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
28 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy, Medical Genetics Unit, Policlinico Tor Vergata, University of Rome Tor Vergata, Rome, Italy
29 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy, Medical Genetics Unit, Policlinico Tor Vergata, University of Rome Tor Vergata, Rome, Italy
30 Myeloid Malignancies Research Group, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain
31 Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
32 Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, United States
33 Department of Molecular Medicine, University of Pavia, Pavia, Italy, Unit of Molecular Hematology and Precision Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
34 Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi University of Florence, Florence, Italy
35 Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I-Sapienza University, Rome, Italy
36 Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
37 Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
38 Catholic University of the Sacred Heart, Rome, Italy, Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
39 Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, Bologna, Italy, Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
40 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
41 Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States
ABSTRACT
Introduction: The gene SH2B3 encodes LNK, a negative regulator of multiple cytokine receptor signaling pathways, including JAK-STAT, through which it restrains cell proliferation. Germline SH2B3 variants have been associated with myeloproliferative disorders in children and adults, but these descriptions are limited. As a result, the full spectrum of manifestations and their relationship to allelic status remain undefined.
Methods: We assembled an international cohort of patients with germline SH2B3 variants, drawn from centers in Italy, Portugal, Spain, Austria, Slovakia, the United States, and Canada. Variant-level data and clinical phenotypes were deposited in an online visualization platform (stjude.org/SH2B3).
Results: We identified 72 patients from 58 families carrying 43 unique germline SH2B3 variants: 29 newly reported patients and 43 previously published patients. Forty-eight patients (66.7%) had a monoallelic variant with somatic loss of heterozygosity (LOH) at SH2B3 occurring in 4/48, while 24 (33.3%) had biallelic variants (21 homozygous and 3 compound heterozygous). Variants included 25 missense and 18 null variants (frameshift: 13, nonsense: 3, and start loss: 2). Eighteen patients (25.0%) carried at least one null mutation (mono or biallelic). The most common variants were p.Glu208Gln (7/72, 9.7%), followed by p.Glu395Lys (5/72, 6.9%), and p.Glu400Lys (4/72, 5.6%). Germline status was confirmed in all cases.
The male/female ratio was 1.2. Median age at clinical presentation was 12 years (y) (range 0-79), with 26 patients (36.1%) presenting <1 y of age. Sixty-eight patients (94.4%) had a hematological abnormality. Median age at onset was 0.1 y (range 0-37) in biallelic and 20 y (range 0-79) in monoallelic cases; 4 individuals were asymptomatic carriers. Twenty-nine patients (40.3%) had a myeloproliferative neoplasm (MPN) [14 thrombocytosis/essential thrombocythemia (ET) progressing to post-ET myelofibrosis (MF) in 2 cases; 8 erythrocytosis/polycythemia vera (PV); 4 primary MF; 1 chronic myelomonocytic leukemia; 2 unclassifiable MPN], while 25 (34.7%) presented with neonatal myeloproliferative disorder (MPD) resembling juvenile myelomonocytic leukemia (JMML), later evolving to thrombocytosis in 4 cases and MF in 1. Eight patients (11.1%) had myelodysplastic syndrome (MDS), 3 (4.2%) idiopathic cytopenias, 2 (2.8%) B-cell acute lymphoblastic leukemia, and 1 (1.4%) acute myeloid leukemia.
Allelic status delineated two distinct phenotypic trajectories: neonatal MPD was the presenting feature in most biallelic cases (n=18), whereas monoallelic carriers most often developed MPN (n=25) at a median age of 12 y, followed by MDS (n=8; 37 y), and idiopathic cytopenias (n=3; 50 y). Seven further monoallelic patients nonetheless presented with neonatal MPD, with somatic LOH detected in 3 and a somatic PTPN11 mutation in 2. Additional somatic mutations were identified in 27 patients (37.5%) and were particularly frequent in myeloid disease: 14/29 (48.3%) with MPN and 6/8 (75%) with MDS.
An autoimmune phenotype affected 15 patients (20.8%), more commonly among biallelic than monoallelic cases (38% vs. 12.2%); 6 of them had >1 autoimmune disease. Half of the cohort (n=36) had splenomegaly or hepatosplenomegaly, including 10 with MPN. Growth restriction or intrauterine growth impairment was confined to the biallelic group, affecting 11/24 patients (45.8%). Facial dysmorphism and developmental delay or cognitive impairment were present in 9 (12.5%) and 11 cases (15.3%), respectively; neither was restricted to the biallelic cohort. Tumors arose exclusively among monoallelic patients, with 3 presenting with malignancies (basal cell carcinoma, breast cancer, and eccrine sweat gland carcinoma) and 2 with benign tumors (uterine fibroma and breast fibroadenoma).
Eleven patients underwent allogeneic hematopoietic cell transplantation (HCT), 8 for neonatal MPD and 1 each for MDS, ET that progressed to AML, and MF. Three deaths were reported: 2 adults with MDS without HCT and 1 child with MPD due to post-HCT veno-occlusive disease.
Conclusions: Together, these findings establish germline SH2B3-associated disease as a distinct syndrome in which systemic manifestations and hematological disease can arise in the absence of detectable somatic drivers. Given favorable outcomes and spontaneous improvement in some patients, early genetic diagnosis is essential to inform therapeutic decisions and structure longitudinal surveillance.